Centauri Therapeutics to Attend Scientific and Investor Conferences
UK, 30 September 2019: Centauri Therapeutics (“Centauri”), an immunotherapy company active in oncology and infectious diseases, announces that it will attend the following scientific and investor conferences:
- IDWeek 2019, 2-6 October 2019 in Washington DC, US
- BioEurope, 11-13 November 2019 in Hamburg, Germany
Jennifer Schneider, Vice President, Business Development, will be attending IDWeek 2019, taking place 2-6 October in Washington DC, US. IDWeek 2019, organized by Infectious Diseases Society of America (IDSA), is an annual scientific conference for health professionals to collaborate, cooperate, and learn from each other’s expertise. With the theme “Advancing Science, Improving Care”, IDWeek 2019 features the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases.
Manjit Rahelu, Chief Business Officer, will be attending BioEurope, taking place 11-13 November in Hamburg, Germany. BioEurope is the largest life science partnering conference in Europe, bringing together biotech and pharma leaders from all around the world to network and discus the latest industry trends.
To arrange a one-to-one meeting with Jennifer or Manjit, please contact info@centauritherapeutics.com.
Notes to editors
Centauri Therapeutics
Centauri Therapeutics is an immunotherapy company focused on oncology and infectious diseases. Centauri’s proprietary Alphamer™ platform is protected by a portfolio of patents and enables the discovery and development of multiple candidate molecules. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases.
For further information, please contact:
Centauri Therapeutics
Manjit Rahelu
Chief Business Officer
+44 1304 728610
For media enquiries:
Consilium Strategic Communications
Matthew Neal, Angela Gray
+44 (0) 20 3709 5700